Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Subsequent Events

Note 13 - Subsequent Events
3 Months Ended
Mar. 31, 2023
Notes to Financial Statements  
Subsequent Events [Text Block]


Subsequent Events


On April 10, 2023, Mr. David Wambeke was appointed Chief Business Officer of DiaMedica. In conjunction with his appointment, Mr. Wambeke purchased 468,750 of DiaMedica’s common shares at an aggregate purchase price of $750,000 or $1.60 per share.


Additionally, the Company granted Mr. Wambeke an inducement stock option to purchase 140,000 common shares of DiaMedica pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan. The stock option has an exercise price of $1.57 per share, which is equal to the closing price of DiaMedica’s common shares on the grant date, and a 10-year term. The option will vest over four years, with 25 percent of the shares underlying the option vesting on the one-year anniversary of the grant date, and the remaining shares vesting in equal quarterly installments over the remaining three years.